Colorectal Cancer
Conditions
Interventions
None listed
Sponsors
Japanese Foundation for Multidisciplinary Treatment of Cancer
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: <1st registration> The metastatic colorectal cancer patients treated with TFTD monotherapy from July 1, 2014 to September 30, 2016. <2nd registration> 1)Patient with ECOG-PS 0 or 1 at the start of TFTD therapy. 2)Patient older than 19 at the time of registration. 3)Patient who receives TFTD at an initial dose of more than -10mg/day/body.
Exclusion criteria
Exclusion criteria: 1)Patients with active double cancer. Carcinoma in situ (intraepithelial carcinoma) or the intramucosal carcinoma equivalent lesion which are concurrent double cancers and heterochronous double cancers within five years, and the investigator judged to cure by topical treatment, are excluded as the double cancer. 2)Infectious disease to be treated. 3)History of severe comorbidities at the start of TFTD. (severe DM, heart failure over NYHA II degree, renal failure, liver failure etc.). 4)Brain metastasis with clinical symptom who need periodical medication (mannitol and steroid, anticonvulsant).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We compare the difference of the overall survival by each reason (RECIST PD, PD by imaging beyond RECIST PD, Clinical PD , adverse event, others) for termination of TFTD. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between overall survival and the therapy prior TFTD Relationship between overall survival and the therapy after TFTD | — |
Countries
Japan
Contacts
Public ContactEIJI OKI
Graduate School of Surgery and Science Kyushu University Department of Surgery and Science
Outcome results
None listed